تحميل...
Quantification of cerivastatin toxicity supports organismal performance assays as an effective tool during pharmaceutical safety assessment
A major problem in pharmaceutical development is that adverse effects remain undetected during preclinical and clinical trials, but are later revealed after market release when prescribed to many patients. We have developed a fitness assay known as the organismal performance assay (OPA), which evalu...
محفوظ في:
| الحاوية / القاعدة: | Evol Appl |
|---|---|
| المؤلفون الرئيسيون: | , , , , , , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
John Wiley and Sons Inc.
2016
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4869410/ https://ncbi.nlm.nih.gov/pubmed/27247619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/eva.12365 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|